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Abstract
Objective: The aim of the present study was to investigate the role of different alpha-foetoprotein
(AFP) determinations in order to propose a new model aimed at predicting intention-to-treat (ITT) death
and post- liver transplantation (LT) recurrence in a cohort of patients with hepatocellular cancer (HCC)
enlisted for LT.
Background: Recent studies have increasingly focused on the role of AFP as a useful tool for patient
selection in the setting of LT for HCC. However, no definitive AFP model has been definitively vali-
dated.
Methods: A retrospective analysis was performed on 124 consecutive patients enlisted for LT in a
UCL Brussels LT centre during the period January 2004 to March 2012. The median follow-up was
3.3 years (ranges: 1.7–6.3).
Results: The area under the receiver-operating characteristic (AUROC) analysis showed the ability of
the AFP delta-slope as a useful prognosticator of tumour-related drop-out and post-LT recurrence. In
multivariate analyses, the delta-slope was an independent predictor of ITT death [hazard ratio
(HR) = 1.014, P < 0.017] and post-LT tumour recurrence (HR = 1.020, P = 0.027). The 5-year ITT
survival and disease-free survival rates were 66.0% versus 36.7% and 92.3% versus 53.8%, for
patients meeting and exceeding the delta-slope cut-off value of 15 ng/ml/month, respectively.
Conclusions: Integration of the AFP delta-slope with conventional criteria may further improve patient
selection and post-LT outcomes; prospective studies are needed to validate the present proposed
model.
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Introduction
Recently, several ‘static’ or ‘dynamic’ alpha-fetoprotein (AFP)
measurements have been proposed as possible tools allowing
the prediction of drop-out (DO) or post-liver transplant (LT)
tumour recurrence in patients with hepatocellular cancer
(HCC).1,2 However, all proposed models have the limit to not
enable to capture the entire behaviour of this marker. Looking
at a picture (static value) or only at some frames (AFP
dynamic value such as a slope based only on two variables)
does not give us the opportunity to understand the entire
‘movie’. As a consequence, until now no definitive AFP cut-off
value has been unanimously accepted.
Unfortunately, AFP modifications present a chaotic beha-
viour. Consequently, the creation of an equation able to
predict the evolution of its casual oscillations and to capture
its trend represents a mathematical challenge.3
Starting from this consideration, the present study has two
different goals: (i) to investigate the role of different AFP
determinations to predict intention-to-treat (ITT) survival and
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post-LT tumour recurrence; and (ii) to propose a new model,
called the AFP delta-slope, with the intent to improve the abil-
ity to predict the risk of death and recurrence.
Patients and material
Data collection
A prospectively collected database, including 143 HCC
patients enlisted for LT at the UCL Transplantation Brussels
during the period January 2004 to March 2012, was used for
the purpose of this study. Inclusion criteria were a radiologi-
cal diagnosis of HCC on pre-LT imaging and age ≥18 years;
exclusion criteria were a mixed tumour, loss of data and less
than two AFP measurements before LT or DO. One hundred
twenty-four patients were finally enrolled in the model
(Fig. 1).
Demographics and tumour characteristics of the entire
cohort and the subcohorts of dropped-out and transplanted
patients are displayed in Table 1. As of 31 January 2015, the
median intent-to-treat follow-up of the entire population was
3.8 years [inter-quartile ranges (IQR): 2.1–6.7].
Tumour diagnosis and selection criteria for liver
transplantation
HCC was diagnosed based on different guidelines according to
the period when LT was performed.4,5 A radiological assess-
ment was always performed at the time of registration on the
waiting list (WL). The University of California San Francisco
criteria (UCSFC) were considered as the upper selection crite-
ria for LT. All the patients presenting a tumour progression
[extra-hepatic pathology or tumour burden exceeding UCSFC
after unsuccessful locoregional treatment (LRT)] during the
WL period were dropped out.
Liver allograft allocation
Graft allocation was based on the laboratory model for end-stage
liver disease (MELD) scoring. Patients with a stage II tumour
according to the International Union against the Cancer (UICC)
and a lab-MELD score beneath 22 were raised to the 22 point
level at registration on the WL.6 Afterwards, further bonus
points were given according to the MELD allocation rules.
Treatment and follow-up of HCC on the waiting list
LRTs were performed according to the European Association
for the Study of the Liver (EASL) guidelines.7 In the present
series, LRTs were adopted in 93.5% of cases, and always when
the tumour burden exceeded the Milan criteria (MC). LRTs
were used in the two different contexts of ‘downstaging’ (DS)
when used in patients exceeding the MC and ‘bridging’ when
meeting the MC. The tumour response after LRT was evalu-
ated using the initial and last imaging before LT according to
the mRECIST (modified Response Evaluation Criteria in Solid
Tumors) criteria.8
Assessment of the evolution of the AFP level
All the available AFP determinations were collected, from the
first HCC radiological detection to LT or DO. The first deter-
mination available in our series corresponded to the AFP value
at the monument of HCC radiological diagnosis: in case of
patients needing DS before WL inscription, an AFP value was
every time performed before LRT. During the WL period, AFP
Figure 1 Flow chart of patients excluded and included in this alpha-fetoprotein (AFP) study
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Table 1 Demographic and clinical data of the entire population of enlisted patients and of the two subgroups of dropped-out and
transplanted patients
Variables Entire population (n = 124) Dropped-out patients (n = 18) Transplanted patients (n = 106)
Median (IQR) or n (%)
Age (years) 60 (56–64) 61 (54–64) 60 (56–64)
Female gender (%) 23 (18.5) 5 (27.8) 18 (17.0)
Underlying cirrhosis cause (%) a
HBV 12 (9.7) 0 (–) 12 (11.3)
HCV 41 (33.1) 5 (27.8) 36 (34.0)
Alcohol 60 (48.4) 9 (50.0) 51 (48.1)
NASH 6 (4.8) 1 (5.6) 5 (4.7)
Other causes 13 (10.5) 4 (22.2) 15 (14.2)
Blood tests at WL inscription
Sodium (mEq/l) 137 (134–139) 137 (134–139) 137 (135–139)
Creatinine (mg/dl) 0.9 (0.7–1.0) 0.9 (0.7–1.2) 0.9 (0.7–1.0)
Albumin (g/dl) 3.2 (2.8–3.6) 3.1 (2.6–3.6) 3.3 (3.0–3.6)
Total bilirubin (mg/dl) 1.7 (1.2–2.6) 2.1 (1.3–3.2) 1.5 (1.1–2.4)
INR 1.20 (1.10–1.30) 1.20 (1.10–1.30) 1.20 (1.10–1.20)
MELD 9 (6–13) 11 (8–14) 9 (6–12)
Radiological HCC features at WL inscription
Number of lesions 1 (1–2) 2 (1–4) 1 (1–2)
Diameter largest lesion (cm) 2.5 (1.8–3.7) 2.6 (2.0–3.9) 2.5 (1.8–3.7)
MC-OUT status (%) 28 (22.6) 8 (44.4) 20 (18.9)
Radiological HCC features before LT or DO
Number of lesions 1 (1–2) 2 (1–3) 1 (1–2)
Diameter largest lesion (cm) 1.7 (0.9–2.8) 2.0 (0.9–5.6) 1.5 (0.9–2.6)
MC-OUT status (%) 28 (22.6) 9 (50.0) 19 (17.9)
LRT (%) 116 (93.5) 17 (94.4) 99 (93.4)
Types (%) b
Liver resection 10 (8.6) 2 (11.8) 8 (8.1)
RF ablation 21 (18.1) 1 (5.9) 20 (20.2)
PEI 41 (35.3) 5 (29.4) 36 (36.4)
TA(C)E 103 (88.8) 17 (100.0) 86 (86.9)
Multiple types of LRTsc 48 (41.4) 7 (41.2) 41 (41.4)
Total number of LRTs 3 (2–4) 3 (2–5) 3 (2–4)
Time last LRT-LT or DO (months) 2 (1–4) 3 (1–6) 2 (1–4)
Downstaging (%) b 28 (24.1) 8 (47.1) 20 (20.2)
Bridging (%) b 88 (75.9) 9 (52.9) 79 (79.8)
mRECIST status (%) b
Complete response 11 (9.4) 2 (11.8) 9 (9.1)
Partial response 38 (32.8) 4 (23.5) 34 (34.3)
Stability 40 (34.5) 2 (11.8) 38 (38.4)
Progression 27 (23.3) 9 (52.9) 18 (18.2)
WL time (months) 6 (3–10) 8 (5–23) 6 (3–10)
aFive cases of HCV + alcohol, 1 case of HBV + HCV, 1 case of HBV + HCV + alcohol.
bPercentages calculated only on patients treated with LRTs (n = 116).
cNumber of patients for different combinations of LRTs : TA(C)E = 55; PEI + TA(C)E = 25; RF + TA(C)E = 9; PEI = 7; RF = 5; RF + PEI + TA(C)E = 5;
resection + TA(C)E = 4; resection + PEI + TA(C)E = 4; resection + RF = 1; resection + RF + TA(C)E = 1.
n, number; IQR, inter-quartile ranges; HBV, hepatitis B virus; HCV, hepatitis C virus; NASH, non-alcoholic steato-hepatitis; WL, waiting list; INR,
international normalized ratio; MELD, model for end-stage liver disease; HCC, hepatocellular cancer; MC, Milan criteria; LT, liver transplantation;
DO, drop-out; LRT, loco-regional treatment; RF, radio-frequency; PEI, percutaneous ethanol injection; TA(C)E, trans-arterial (chemo)embolization;
mRECIST, modified response evaluation criteria in solid tumours.
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was systematically performed every month. The last AFP mea-
surement corresponded to the value obtained immediately
before LT or at the moment of DO. In case of the LRT being
performed during the WL period, AFP was measured immedi-
ately before the procedure and 1 month after.
Four different AFP variables were investigated in the pre-
sent study: (i) the last static AFP value; (ii) the slope of AFP
evolution; (iii) the pre-LRT AFP delta-slope; and (iv) the
post-LRT AFP delta-slope. The slope of AFP progression was
calculated according to Vibert et al., considering the differ-
ence between AFP values divided by the time-lapse between
two referral points.2 The referral points were the AFP value
immediately before the last LRT and the last determination
before LT or DO. The AFP delta-slope was obtained by cal-
culating the delta-value between the two different slopes. The
mathematical model proposed is based on the following
formula:
ðAFP3  AFP2Þ
t3  t2
 
 ðAFP2  AFP1Þ
t2  t1
 
(i) AFP1 and t1 correspond to the AFP determination and
time at the moment of HCC diagnosis; and (ii) AFP3 and t3
correspond to the AFP measure and time immediately before
LT or DO.
When the pre-LRT AFP delta-slope is calculated: AFP2 and
t2 correspond to the AFP measurement and the time immedi-
ately before the last LRT. When the post-LRT AFP delta-slope
is calculated: AFP2 and t2 correspond to the AFP measurement
and the time immediately after the last LRT.
In the eight patients not treated with LRT during the wait-
ing time, we arbitrarily decided to calculate both the two
slopes using the same last three AFP values obtained before LT
or DO.
Different cut-off values were tested in the analysed AFP vari-
ables. The threshold value of 400 ng/ml was considered in the last
static AFP examination.9 A threshold value of 15 ng/ml/month
was considered in the AFP slope, as previously reported.2,3 For
AFP delta-slopes, we arbitrarily decided a similar cut-off of
15 ng/ml/month, corresponding to an 85th centile of the cohort.
Immunosuppression
Immunosuppressive therapy consisted of a triple-drug
calcineurin inhibitor (CNI)-based regimen in combination
with steroids and either azathioprine or mycophenolic acid.
Steroids were gradually tapered and discontinued after 3–
6 months in nearly all patients. M-TOR-Inhibitors were also
introduced in case of renal dysfunction, HCC recurrence or
the development of a de-novo tumour.
Patient follow-up
All patients were followed in the transplant outpatient clinic.
Screening for tumour recurrence was done using the measure-
ment of AFP levels and ultrasound examination every 3 months.
Thoraco-abdominal CT-scan was performed every 6 months;
additional bone scan was done in the case of suspected HCC
recurrence. No patient received adjuvant chemotherapy.
Statistical analysis
Categorical variables were reported as the number of cases and
percentages; continuous variables as medians and IQRs. Com-
parisons were performed using Pearson’s chi-square test, Fish-
er’s exact test in case of categorical variables; continuous
variables were compared using Student’s t-test (variables with
a parametric distribution) and Mann–Whitney U-test (vari-
ables with non-parametric distribution).
Last static AFP determination, the slope of AFP and delta-
slope were tested in the two different settings of ITT death and
post-LT recurrence using c-statistics analysis. The area under
the receiver-operating characteristic (AUROC) curve was calcu-
lated with the intent to evaluate the prognostic ability of the
variables. Different cut-offs of these variables were also investi-
gated, as previously reported2,3,9. The diagnostic odds ratio
(DOR), which measures the overall accuracy of a diagnostic
test, was calculated for each cut-off value. A higher DOR indi-
cates a higher accuracy of the test.
Multivariate Cox’s regression analysis was performed with
the intent to investigate risk factors for ITT patient death and
post-LT recurrence. Only variables detectable prior to LT or
DO were analysed. Only variables with a P-value ≤ 0.20 by
univariate analysis were included in the models. The goodness
of fit for the models was tested with the 2 Log Likelihood.
Prediction of risk was reported as hazard ratios (HR), 95%
confidence intervals (CI) and P-value. A P-value < 0.05 indi-
cated statistical significance.
ITT patient and disease-free survival (DFS) rates were anal-
ysed by the Kaplan–Meier method and compared using the
log-rank test. Statistical analyses and plots were performed
using SPSS 19.0 (SPSS, Chicago, IL, USA).
Results
Analyses of tumour lesions and outcome of patients
Eighteen (14.5%) out of the 124 patients dropped out (DO
group), with a median follow-up from WL inscription of
11 months (IQR: 8–33). At initial radiology (WL inscription),
10 (55.6%) patients were MC-IN and 8 (44.4%) were MC-
OUT but UCSFC-IN. At final radiology (immediately before
DO), 9 (50.0%) dropped out owing to extra-hepatic HCC
pathology (n = 4) or a tumour burden exceeding UCSFC crite-
ria after an unsuccessful LRT (n = 5). In 9 (50.0%) cases,
despite a stable HCC pathology, patients dropped out for
tumour-unrelated causes. Reasons for no tumour-related DO
were death from terminal liver failure (n = 5), clinical worsen-
ing (n = 3) and poor compliance (n = 1).
One hundred six patients were transplanted (LT group),
with a median follow-up after transplantation of 3.4 years
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(IQR: 1.7–6.2). Thirteen (12.3%) of the 106 patients who
underwent LT had a recurrence (Fig. 1).
A total number of 116/124 (93.5%) patients was treated with
LRTs. According to mRECIST criteria, 6/17 (35.3%) DO and
43/99 (43.4%) LT patients previously treated with LRT had a
radiological tumour response; 9/17 (52.9%) DO and 18/99
(18.2%) LT patients had tumour progression (Table 1).
Pathology of the hepatectomy specimen revealed an
MC-OUT status in 19 (17.9%) out of the 106 transplanted
patients. Complete necrosis at the site of LRT was seen in 30
(28.3%) patients; tumour progression in 17 (16.0%) patients.
Poor grading (Edmondson grade 3–4) was reported in 44
(41.5%) patients. Micro- and macro-vascular invasion were
seen in 29 (27.4%) and 4 (3.8%) cases (Table 2).
AFP variables
A median number of 4 (IQRs: 3–6) AFP measurements was
performed in the entire population. The median time from
first AFP measure (HCC radiological diagnosis) to WL inscrip-
tion was 0.8 months; the time from the first AFP measure to
LT or DO was 7 months (IQR 4–12). The time from AFP
determination before the last LRT and LT or DO was
3.1 months; the time from AFP measure after the last LRT and
LT or DO was 1.8 months.
Table 2 Transplant and pathological data of the group of transplanted patients and of the two subgroups of recurred and no-recurred
patients
Variables Transplanted patients (n = 106) Recurred patients (n = 13) No-recurred patients (=93)
Median (IQR) or n (%)
Donor age (years) 53 (40–62) 49 (32–69) 53 (41–62)
Donor Risk Index 1.62 (1.29–1.96) 1.48 (1.15–2.04) 1.63 (1.31–1.96)
Recipient blood tests at LT
Sodium (mEq/l) 137 (134–139) 137 (134–141) 137 (134–139)
Creatinine (mg/dl) 0.88 (0.72–1.10) 0.91 (0.72–1.50) 0.87 (0.71–1.08)
Albumin (g/dl) 3.4 (2.9–3.9) 3.0 (2.5–3.6) 3.4 (3.1–3.9)
Total bilirubin (mg/dl) 1.5 (0.9–2.4) 1.5 (1.1–2.4) 1.5 (0.9–2.5)
INR 1.18 (1.10–1.30) 1.20 (1.15–1.27) 1.18 (1.07–1.31)
MELD 9 (6–13) 10 (7–14) 8 (6–13)
Radiological HCC features at LT
Number of lesions 1 (1–2) 1 (1–2) 1 (1–2)
Diameter largest lesion (cm) 1.5 (0.9–2.6) 2.0 (1.3–3.2) 1.5 (0.7–2.7)
MC-OUT status (%) 19 (17.9) 3 (23.1) 16 (17.2)
HCC features at pathology
Number of lesions 2 (1–3) 2 (1–5) 2 (1–3)
Diameter largest lesion (cm) 2.0 (1.2–3.0) 3.7 (2.0–4.5) 2.0 (1.0–3.0)
Grading (%)
1 4 (3.8) 0 (–) 4 (4.3)
2 26 (24.5) 1 (7.7) 25 (26.9)
3–4 44 (41.5) 8 (61.5) 36 (38.7)
Necrosis 22 (20.8) 1 (7.7) 21 (22.6)
NA 10 (9.4) 3 (23.1) 7 (7.5)
Microvascular invasion (%) 29 (27.4) 7 (53.8) 22 (23.7)
Macrovascular invasion (%) 4 (3.8) 1 (7.7) 3 (3.2)
Necrosis rate at pathology (%)
100% 30 (28.3) 1 (7.7) 29 (31.2)
50–99% 31 (29.2) 2 (15.4) 29 (31.2)
20–49% 28 (26.4) 6 (46.2) 22 (23.7)
<20% 17 (16.0) 4 (30.8) 13 (14.0)
n, number; IQR, inter-quartile ranges; LT, liver transplantation; INR, international normalized ratio; MELD, model for end-stage liver disease; HCC,
hepatocellular cancer; MC, Milan criteria; NA, not available.
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Comparing transplanted patients with DO patients, the latter
ones presented both a higher AFP at the moment of LT or DO
(median value: 7.3 versus 45.0 ng/ml; P-value 0.004) and AFP
slope values (median value: 0.05 versus 7.2 ng/ml/month; P
value 0.001). Similarly, patients with post-LT recurrence had
both a higher AFP at the moment of LT (median value: 6.9
versus 45.0 ng/ml; P-value 0.004) and AFP slope values
(median value: 0.001 versus 9.6 ng/ml/month; P value 0.001)
with respect to transplanted patients without recurrence after LT
(Table 3).
Last static AFP, AFP slope and delta-slopes had similar
AUROC curves for the risk of intention-to-treat death (60.4,
64.4, 64.6 and 64.2, respectively). Last AFP ≥400 ng/ml had a
good DOR (6.6), but poor sensitivity (14.9%). AFP slope and
pre-LRT AFP delta-slope had good AUROC curves for the
risk of post-LT recurrence (79.8 and 79.4, respectively); a pre-
LRT AFP delta-slope ≥15 ng/ml/month had the best DOR
(7.1), with 46.2% of sensitivity and 89.2% of specificity
(Table 4).
Multivariate analyses for the risk of ITT death and
post-LT recurrence
Only the diameter of the largest lesion before DO or LT (HR 1.260; P-
value 0.001) and pre-LRT AFP delta-slope (HR 1.014; P-value 0.017)
were statistically significant as risk factors for ITT death (Table 5).
Similarly, the same variables were significant risk factors for
post-LT recurrence: tumour diameter had an HR of 1.499 (P-
value 0.032) and a pre-AFP delta-slope of 1.020 (P-value 0.027)
(Table 5).
ITT patient survival and post-LT recurrence
Analysing the entire population, 1-, 3- and 5-year ITT patient
survival rates were 82.1%, 68.9% and 59.9%, respectively.
When stratifying the entire population using the different AFP
measurements, slope and the pre-AFP delta-slope both allowed
better results to be obtained in terms of ITT survival, with a
6% increase at 5 years compared with the entire population
(Fig. 2a, Table 6).
When looking at DFS, the pre-LRT AFP delta-slope was the
best tool for stratification, allowing a 6.4% increase to be
obtained at 5 years when compared with the entire population
(92.3 versus 85.9%) (Fig. 2b, Table 6).
Subanalysis #1: AFP delta-slope and mRECIST
response
Stratifying the entire cohort according to the pre-LT radiologi-
cal response based on the mRECIST classification, a greater
number of patients with a pre-LRT AFP delta-slope ≥15 ng/
ml/month was observed in patients with progressive pathology
(10/27, 37.0%) compared with patients with a stable (5/40,
12.5%), partial response (5/37, 13.5%) or complete response
(1/10, 10.0%) (P-value 0.022).
At ITT survival analysis, the pre-LRT AFP delta-slope
≥15 ng/ml/month was able to discriminate among patients
only in the subgroup of recipients with tumour progression
(5 year: 57.4% versus 12.1%; P-value 0.034). At DFS analysis, a
pre-LRT AFP delta-slope ≥15 ng/ml/month was able to signifi-
cantly discriminate among patients in the two subgroups of
recipients with stable (5 year: 88.0 versus 33.0%; P-value
Table 3 AFP data in the entire population, dropped-out, transplanted and post-LT recurred patients
Variables Entire population
(n = 124)
Dropped-out
patients (n = 18)
Transplanted
patients (n = 106)
Post-LT recurrence
patients (n = 13)
Median (IQR) or n (%)
AFP (ng/ml)
At HCC radiological diagnosis 8.0 (4.0–31.1) 13.5 (5.3–133.3) 8.0 (3.8–29.3) 15.7 (8.6–27.9)
Last value before LT or DO 8.0 (3.9–46.0) 45.1 (4.0–530.6) 7.3 (3.8–31.5) 45.0 (9.2–120.0)
>400 ng/ml (%) 8 (6.5) 4 (22.2) 4 (3.8) 2 (15.4)
AFP-slope (ng/ml/month) 0.1 (0.9–4.2) 7.2 (1.0–298.8) 0.05 (0.8–2.1) 9.6 (0.7–17.6)
>15 ng/ml/month (%) 24 (19.4) 8 (44.4) 16 (15.1) 5 (38.5)
Pre-LRT-LT AFP delta-slope (ng/ml/month) 0.05 (0.4–3.6) 3.0 (1.2–298.8) 0.05 (0.4–2.0) 3.3 (0.8–15.5)
>15 ng/ml/month (%) 25 (20.2) 7 (38.9) 17 (16.0) 5 (38.5)
Post-LT-LT AFP delta-slope (ng/ml/month) 0.2 (0.5– 5.3) 5.8 (0.1–298.8) 0.1 (0.5–3.2) 4.9 (1.6–22.6)
>15 ng/ml/month (%) 22 (17.7) 7 (38.9) 15 (14.2) 4 (30.8)
Number of AFP measurements 4 (3–6) 4 (3–7) 4 (3–6) 6 (3–6)
Time first AFP-WL inscription (months) 0.8 (0.3–1.6) 1.0 (0.4–1.6) 0.7 (0.3.1.6) 0.5 (0.1–2.5)
Time first AFP-LT or DO (months) 7 (4–12) 8 (6–25) 7 (4–11) 7 (5–10)
Time AFP before last LRT-LT or DO (months)a 3.1 (2.1–5.8) 2.4 (1.7–3.2) 3.6 (2.3–5.9) 4.7 (2.3–7.1)
Time AFP after last LRT-LT or DO (months)a 1.8 (0.9–4.4) 1.2 (0.8–2.7) 1.9 (0.9–4.7) 2.4 (1.0–5.0)
aFor patients not treated with LRT the last but one AFP measurement was considered.
LT, liver transplantation; n, number; IQR, inter-quartile ranges; AFP, alpha-foetoprotein; WL, waiting list; LT, liver transplantation; DO, drop-out.
HPB 2015, 17, 1085–1095 ª 2015 International Hepato-Pancreato-Biliary Association
1090 HPB
0.012) and progressive tumour pathology (5 year: 100.0 versus
50.0%; P-value 0.034).
Subanalysis #2: AFP delta-slope and underlying liver
pathology
After stratification of the entire cohort according to the main
underlying liver pathologies (HCV and alcohol), a pre-LRT
AFP delta-slope ≥15 ng/ml/month was not able to significantly
discriminate in terms of ITT survival in both the subgroups of
patients with alcohol-related cirrhosis (5 year: 62.4 versus
37.5%; P-value 0.077) and HCV-related cirrhosis (5 year: 60.6
versus 46.9%; P-value 0.413). Similar DFS rates were observed
in patients with alcohol-related cirrhosis (5 year: 90.5 versus
60.0%; P-value 0.119) and HCV-related cirrhosis (5 year: 83.1
versus 75.0%; P-value 0.797). Unfortunately, the small number
of HBV- and NASH-related patients limited the opportunity to
obtain solid statistical data; consequently, they were not inves-
tigated.
Discussion
Despite the development of the MC, justification of LT for
HCC still represents a daily challenge. This statement is true
mainly when taking into consideration the still elevated
percentage of DO patients on the WL owing to tumour
progression (5–10%) or experiencing recurrence after LT
(10–15%).10,11 Obviously, the different clinical approaches that
are adopted in different scenarios directly influence these
results. For example in Eastern countries, recurrence rates
raised to 20–25%, while the percentage of DO patients remains
lower owing to the use of (fast-track) living donation.12
Despite these differences, it is not so far from the truth that
up to one-fifth of HCC patients listed for LT die as a result of
the native or recurrent tumour. Presently, 7.3% of patients
dropped out due to HCC progression, and 10.5% had a post-
LT recurrence, confirming the datum that about one-fifth of
patients experience a tumour-related negative course.
Up until now only morphological features, the number and
the diameter of nodules, have been unanimously recognized as
an efficacious selection tool for LT.13 Several attempts to
enlarge the MC have been advocated in order to increase the
number of potentially transplantable candidates.14 Unfortu-
nately, morphology alone is unable to capture fully tumour
aggressiveness.15,16 Indeed the more one deviates from the MC,
Table 4 Receiver-operating characteristic analysis and cut-off values of different alpha-fetoprotein measurements in the settings of ITT
death and post-LT recurrence
Variables AUC 95% CI SE P-value Cut-off Sensitivity Specificity DORa
Intention-to-treat death
Last AFP 60.4 49.6–71.2 0.06 0.05 400 ng/ml 14.9 97.4 6.6
AFP-slope 64.4 54.0–74.8 0.05 0.007 15 ng/ml/month 31.9 89.6 4.0
Pre-AFP delta-slope 64.6 54.3–75.0 0.05 0.006 15 ng/ml/month 29.8 88.3 3.2
Post-AFP delta-slope 64.2 53.8–74.6 0.05 0.008 15 ng/ml/month 25.5 85.7 2.0
Post-LT recurrence
Last AFP 74.8 61.3–88.3 0.07 0.004 400 ng/ml 15.4 97.8 6.0
AFP-slope 79.8 68.4–91.2 0.06 0.001 15 ng/ml/month 38.5 88.2 4.8
Pre-AFP delta-slope 79.4 67.8–91.0 0.06 0.001 15 ng/ml/month 46.2 89.2 7.1
Post-AFP delta-slope 74.0 57.9–90.1 0.08 0.005 15 ng/ml/month 30.8 88.2 3.3
aDOR is calculated according to the following formula: [(sens)/(1-sens)]/[(1-spec)/(spec)].
AUC, area under the curve; CI, confidence interval; SE, standard error; DOR, diagnostic odds ratio; AFP, alpha-foetoprotein; LT, liver transplanta-
tion.
Table 5 Multivariable Cox regression models analysing the risk
factors for intention-to-treat patient death and post-LT recurrence
(backward stepwise methodics)
Variable ITT patient death (n = 124)
P-value HR 95% CI
Diameter of the largest
lesion before DO or LT
0.001 1.260 1.100–1.442
Pre-LRT AFP delta-slope 0.017 1.014 1.002–1.025
2 Log Likelihood: 405.873
Variable Post-LT recurrence (n = 106)
P-value HR 95% CI
Diameter of the largest
lesion before DO or LT
0.032 1.499 1.036–2.170
Pre-LRT AFP delta-slope 0.027 1.020 1.002–1.038
2 Log Likelihood: 101.907
Variables initially analysed in the models: Time of LT (per year), HCV
status, number of tumor lesions before DO or LT, diameter of the
largest lesion before DO or LT, MC-OUT status before DO or LT,
MELD before DO or LT, locoregional treatment, downstaging,
mRECIST progression, AFP slope, pre-LRT AFP delta-slope, post-LRT
AFP delta-slope, last AFP.
ITT, intention-to-treat; HR, hazard ratio; CI, confidence interval; LT,
liver transplantation; LRT, loco-regional treatment; AFP, alpha-foeto-
protein; mRECIST, modified response evaluation criteria in solid
tumours; DO, drop-out; HCV, hepatitis C virus; MC, Milan criteria;
MELD, model for end-stage liver disease.
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the higher the recurrence rate will be.17 As a consequence, the
main problem to solve relates to the detection of pre-opera-
tively available predictors that are contemporaneously able to:
(i) exclude very high-risk tumours, even when remaining
within the conventional criteria; and (ii) include patients pre-
senting biologically indolent HCC even when out of conven-
tional criteria. Such a model will theoretically impact only on
a small number of patients (5–10%), owing to its intent to
comply with the stringent dichotomy ‘transplantation versus
no transplantation’.
Recently, AFP has been investigated with this intent18 and
several studies indeed showed its ability to predict microvascu-
lar invasion, drop-out and recurrence.19,20 Some authors,
mainly from Eastern countries, already proposed models com-
bining tumour morphology and AFP or other HCC markers.
The Hangzhou Criteria (total tumour diameter ≤ 8 cm; or
total tumour diameter >8 cm but with histopathologic grade I
or II and a pre-operative AFP level ≤ 400 ng/ml, simultane-
ously)21 and the Kyoto criteria (≤ 10 tumours all ≤ 5 cm in
diameter and protein induced by vitamin K absence or
antagonist-II ≤400 mAU/ml) are good examples of this strat-
egy.22 However, none of them obtained an international con-
sensus, mainly owing to the difficulty to confirm the validity
of a monocentric model in other scenarios.
Beside this, several other questions remain unanswered
about the use of AFP, such as the best type of measurement to
adopt (static versus dynamic) and the best cut-off to use.
A recent multicentre French study identified a last pre-LT
AFP measurement >1000 ng/ml as a risk factor for recurrence
in HCC MC-IN patients.3 A monocentric US study similarly
underlined the prognostic role of a last AFP >1000 ng/ml in a
cohort of MC-IN patients.23 Another French monocentric
study focused on the role of the AFP slope, stressing thereby
the role of AFP ‘dynamics’ during waiting time; a cut-off value
of 15 ng/ml/month was identified to have prognostic value.4
Finally, a multicentric European study confirmed the validity
of the AFP slope in both sub-cohorts of MC-IN and MC-OUT
patients.24
In the present study, we tested and compared the role of dif-
ferent AFP measurements in a same cohort of liver recipients.
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Figure 2 (a) Intention-to-treat survival rates according to the alpha-fetoprotein (AFP) delta-slope model; (b) disease-free survival rates
according to the AFP delta-slope model
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We initially decided to test two different types of delta-slope
(namely, the ‘pre-LRT’ and the ‘post-LRT’ one) with the intent
to avoid possible bias derived from the different lengths of
time used into the two equations. For example, if we compare
two patients with an initial AFP of 10 ng/ml waiting for
20 months before the last LRT, with identical pre- and post-
LRT AFP values of 30 ng/ml and a pre-LT value of 50 ng/ml,
only the patient having a shorter (1 month) time between
post-LRT and pre-LT AFP measurements will be ‘at-risk’
(≥15 ng/ml/month) compared with the other one having a
period of 2 months between the pre-LRT and the pre-LT AFP
measurements. When applying the equations to the analysed
population, a slight difference in terms of selected patients was
observed (25 ‘pre-LRT’ versus 22 ‘post-LRT’ patients); how-
ever, the pre-LRT algorithm showed a better discriminatory
power. In fact, despite concerns that the effective biology of
AFP rise after LRT would not be reflected using the ‘pre-LRT’
algorithm, we can assume that the last AFP determination itself
reflects the effectiveness of the LRT, equally or even more than
the first AFP measure obtained immediately after such a treat-
ment.
From a practical point of view, the last AFP measurement
and AFP slope are easier to calculate in comparison with the
pre-LRT delta-slope, because they are based only on one or
two values. However, despite the fact that the delta slope
requires three values to be taken into consideration, it allows a
reduction in the percentage of data loss which in turn allows
better capture of the AFP fluctuations during the WL period.
A slope and pre-LRT delta-slope were similar in predicting
ITT death; but interestingly enough the pre-LRT delta-slope
was superior with respect to slope in its ability to predict post-
LT tumour recurrence (DOR 7.1 versus 4.8 using in both the
cases a cut-off value of 15 ng/ml/month). This ability was fur-
ther underpinned when analysing survival, with a pre-LRT
delta-slope ≥ 15 ng/ml/month allowing better discrimination
between the patients with a greater or lower risk of recurrence.
Adopting a backwards stepwise method in constructing the
multivariable Cox regression model, only the pre-LRT delta-
slope remained significant among the different AFP measure-
ments.
Obviously, the main problem in using any AFP measure-
ment as a tool for selecting patients waiting for LT is because
AFP alone does not fit all in the patient selection. Interpreta-
tion of AFP values varies widely and its use is at different
swings of the pendulum. As a consequence, most authors agree
that AFP is not an ‘all-or-none’ determinant and that it should
be used in concordance with other risk factors, such as imag-
ing criteria. In fact, the hypothetical adoption of the pre-LRT
delta-slope as a single discriminating variable in the present
series should ultimately end in an unacceptable high reduction
rate of transplantable patients (25 on 124: 20.1% of cases).
Such datum is not in line with other experiences, in which the
adoption of specific models based on AFP values showed a
reduction in transplantable patients ranging from 4.7% to
6.2%.23,24 In the latter cases, a very high AFP cut-off
(>1000 ng/ml) was used, with the obvious intent to simultane-
ously reduce the HCC recurrence rate and to avoid excluding
too many patients from LT without post-LT recurrence.25
Another confirmation of the fact that AFP should be used in
combination with imaging derives from the sub-analysis
focused on the impact of the AFP delta-slope in different sub-
groups of patients according to the mRECIST status after LRT.
The higher AFP discriminative ability was observed in patients
with tumour progression: this can be explained by the consid-
eration that AFP levels are strongly influenced by successful or
Table 6 Intention-to-treat patient survival and post-LT disease-free
survival rates according to different AFP measures
Variables 1-year 3-year 5-year P-value
ITT-survival
Entire cohort
n = 124 82.1 68.9 59.9 –
Last AFP
<400 ng/ml (n = 116) 84.4 70.1 62.8 0.017
≥400 ng/dl (n = 8) 50.0 50.0 18.8
AFP slope
<15 ng/ml/month (n = 100) 86.9 74.9 66.3 0.002
≥15 ng/dl/month (n = 24) 62.5 44.9 34.9
Pre-AFP delta-slope
<15 ng/ml/month (n = 99) 86.7 74.6 66.0 0.005
≥15 ng/dl/month (n = 25) 64.0 47.5 36.7
Post-AFP delta-slope
<15 ng/ml/month (n = 102) 86.2 72.1 64.0 0.031
≥15 ng/dl/month (n = 22) 63.6 53.7 39.2
Disease-free survival
LT cohort
n = 106 94.6 85.9 85.9 –
Last AFP
<400 ng/ml (n = 102) 94.3 87.9 87.9 0.043
≥400 ng/dl (n = 4) 100.0 50.0 50.0
AFP slope
<15 ng/ml/month (n = 90) 93.7 90.7 90.7 0.011
≥15 ng/dl/month (n = 16) 100.0 58.3 58.3
Pre-AFP delta-slope
<15 ng/ml/month (n = 89) 93.6 92.3 92.3 0.002
≥15 ng/dl/month (n = 17) 100.0 53.8 53.8
Post-AFP delta-slope
<15 ng/ml/month (n = 91) 93.7 89.6 89.6 0.098
≥15 ng/dl/month (n = 15) 100.0 64.8 64.8
ITT, intention-to-treat; AFP, alpha-foetoprotein; LT, liver transplanta-
tion.
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unsuccessful LRTs. As a consequence, the AFP delta-slope may
represent a kind of surrogate of an effective radiological treat-
ment. Recent studies showed that a radiological response in
combination with AFP dynamics indeed may predict post-LT
recurrence.24
When specifically looking at the differences in AFP levels
among patients with different underlying liver diseases, the use
of pre-LRT AFP delta-slope did not differ. This finding could,
however, be influenced by the small number of cases observed
in each subgroup, especially in HBV- and NASH-related cir-
rhosis.
The presently discussed delta-slope model represents an
innovative selection approach in HCC patients for LT. Obvi-
ously, some limitations should at this moment be taken into
consideration. First, despite the fact that the pre-LRT AFP
delta-slope was superior to other AFP measurements, its
discriminative power was in relatively slight, as shown by the
AUROC analysis. As a consequence (as underlined above) it
seems unfair to exclude patients from LT based only upon this
parameter. Moreover, the relatively short length of follow-up
after LT (median 3.3 years), the small number of patients
included and the low number of HCC recurrences further limit
the solidity of the statistical results. Further validations in lar-
ger series are, therefore, required. However, it should be
stressed that the main intent of the present study was not to
find a new ‘exclusive’ selection criterion, but to preliminarily
show the potential utility of changes in AFP measurements in
relation to survival and, therefore, as an integrative selection
tool. Moreover, except the Duvoux study,1 all published studies
in this field of LT have the limit of being a single centre and
retrospective.
In conclusion, the pre-LRT AFP delta-slope may represent
an additional and useful tool to analyse the entire evolution of
AFP during the waiting list period, allowing identification of
the effective oscillations of AFP during the waiting time period.
Prospective studies performed on larger populations are
needed to validate the proposed model combined with mor-
phological features as an improved selection tool for LT. This
may be of particular value, especially when taking into account
the, recently reported, widening of inclusion criteria of HCC
patients for transplantation.
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